查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1379994

蛋白质工程市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品类型、技术、最终用户和地区、竞争细分

Protein Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product Type, Technology, End User, and By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球蛋白质工程市场价值为 25.6 亿美元，预计到 2028 年，预测期内将出现令人印象深刻的增长，复合CAGR为11%。蛋白质工程是生物技术的一个分支，涉及精心设计、修改和优化蛋白质来创造新功能、改进现有功能或针对特定应用客製化它们。蛋白质是重要的生物大分子，在生物体中发挥广泛的功能，包括催化化学反应（酵素）、运输分子、提供结构支持和调节细胞过程。蛋白质工程利用对蛋白质结构和功能的理解来操纵这些分子以达到各种目的。分子生物学技术的进步使得合成和修饰编码具有特定序列的蛋白质的基因成为可能。这使得研究人员能够创造全新的蛋白质或修改现有的蛋白质以适应各种应用。

主要市场驱动因素

市场概况
预测期 2024-2028
2022 年市场规模 25.6亿美元
2028 年市场规模 47.6亿美元
2023-2028 年CAGR 11.00%
成长最快的细分市场 疫苗
最大的市场 北美洲

技术进步

蛋白质工程的技术进步在塑造该领域并扩大其在各个行业（包括製药、生物技术、农业和工业流程）的应用方面发挥了关键作用。成簇规则间隔短回文重复序列 (CRISPR) 和 CRISPR 相关蛋白 9 (Cas9) 技术彻底改变了蛋白质工程。它允许精确的基因组编辑，使得高特异性和高效地修改基因和工程蛋白质成为可能。这对药物开发、农业和基础研究有深远的影响。定向进化是一种强大的技术，可以模仿自然选择来优化蛋白质的特定功能。透过迭代的突变和选择，研究人员可以设计具有增强特性的蛋白质，例如增加亲和力、稳定性或酶活性。高通量筛选 (HTS) 方法变得更加复杂和自动化，能够快速筛选大型蛋白质库以获得所需的特性。这加速了新型酵素、治疗抗体和其他基于蛋白质的产品的发现。包括分子建模和机器学习在内的计算方法的进步使研究人员能够预测工程蛋白质的结构和功能。这可以节省设计阶段的时间和资源，并有助于理解蛋白质-配体相互作用。合成生物学技术能够创造全新的蛋白质和生物系统。研究人员可以设计和合成编码具有客製化功能的新型蛋白质的基因，从而扩大蛋白质工程的可能性。蛋白质表现系统（例如酵母、细菌和哺乳动物细胞）的改进增强了重组蛋白和治疗抗体的产生。这些进步提高了工程蛋白质的产量和品质。

了解蛋白质折迭和稳定性对于蛋白质工程至关重要。计算工具和实验技术改进了蛋白质结构和稳定性的预测，有助于设计更稳健的蛋白质。下一代定序（NGS）技术促进了遗传变异和表现模式的分析，使研究人员能够更有效地识别和表征潜在的蛋白质工程标靶。无细胞蛋白质合成系统变得更有效率和通用。它们无需活细胞即可快速生产蛋白质，更容易设计和研究各种蛋白质。 CrispRGold 和 Prime Editing 等基因组编辑技术的最新发展为修改基因序列提供了更高的精度和控制。这些进步对基因治疗和蛋白质工程有深远的影响。 ChIP-seq 和蛋白质-DNA 交联等技术使研究人员能够在分子层面上研究蛋白质-DNA 相互作用。这对于理解基因调控和设计 DNA 结合蛋白至关重要。单细胞蛋白质体学技术的进步可以分析单一细胞的蛋白质含​​量，从而深入了解细胞异质性和疾病机制。这项因素将有助于全球蛋白质工程市场的发展。

不断发展的生物技术和製药行业

生物技术和製药行业见证了向生物製剂的转变，生物製剂是从活生物体中提取的药物。这包括单株抗体、疫苗和其他基于蛋白质的疗法。蛋白质工程在设计、优化和生产这些生物製品方面发挥着至关重要的作用，满足了对更有针对性和更有效的治疗日益增长的需求。发现和开发新药的过程通常涉及与疾病相关的特定蛋白质的识别和修饰。蛋白质工程技术能够修饰这些蛋白质，以增强其治疗特性或创造全新的候选药物。製药业越来越倾向于个人化医疗，即根据患者的个人情况量身定制治疗方案。蛋白质工程允许客製化治疗蛋白质，以匹配个别患者的遗传和分子特征，从而改善治疗结果。蛋白质工程在罕见疾病和孤儿疾病疗法的开发中发挥了重要作用，这些疾病可能没有大量的患者群体。製药业对这些利基市场表现出了兴趣，推动了对蛋白质工程服务和技术的需求。

生物製药产业依靠生物製造流程来生产大量的蛋白质药物。蛋白质工程有助于优化这些治疗性蛋白质的表达、产量和稳定性，确保高效且经济高效的生产。製药公司不断寻求透过创新和差异化产品来扩大其药物管道。蛋白质工程可以开发新型生物製剂和以蛋白质为基础的疗法，帮助公司保持竞争力。联合疗法的开发，即使用多种药物来针对疾病的不同方面，是製药业的成长趋势。蛋白质工程可用于设计协同作用的互补治疗性蛋白质。随着一些生物药物的专利到期，生物相似药的市场不断增长，生物相似药是现有生物製剂的高度相似版本。蛋白质工程用于製造具有可比较功效和安全性的生物相似药。生技和製药公司大力投资研发，将新药推向市场。这项投资包括蛋白质工程研究和技术开发的资金。製药公司、生物技术公司和学术机构在蛋白质工程研究方面的合作已变得普遍。这些合作伙伴关係推动创新并加速以蛋白质为基础的疗法的开发。 COVID-19 大流行等事件凸显了快速开发疫苗和治疗方法的必要性。蛋白质工程在 COVID-19 疫苗和治疗方法的开发中发挥了关键作用，展示了其在应对全球健康挑战方面的重要性。这项因素将加快全球蛋白质工程市场的需求。

更关注罕见疾病

罕见疾病，也称为孤儿病，由于发病率低，往往缺乏有效的治疗方法。蛋白质工程提供了一种有前途的方法来开发针对这些疾病的客製化疗法，解决重大的未满足的医疗需求。对罕见疾病的研究通常涉及识别这些疾病背后的特定基因突变或蛋白质异常。蛋白质工程允许客製化治疗性蛋白质，以精确靶向罕见疾病所涉及的分子途径，从而实现精准医学方法。世界各地的政府和监管机构为治疗罕见疾病的孤儿药的开发提供激励措施。蛋白质工程有助于设计和优化这些药物，包括单株抗体和酵素替代疗法。罕见疾病通常是由特定蛋白质异常引起的。蛋白质工程技术能够开发出能够纠正或补偿这些异常的标靶疗法，从而改善治疗结果。

针对罕见疾病相关蛋白质而设计的单株抗体在治疗某些形式的肌肉营养不良症和溶酶体贮积症等疾病方面显示出巨大的前景。蛋白质工程与基因疗法密切相关，基因疗法在治疗罕见遗传性疾病方面具有巨大潜力。工程蛋白质，例如病毒载体或酶，可用于向罕见疾病患者传递治疗基因。对于某些罕见的代谢性疾病，酵素替代疗法至关重要。蛋白质工程技术可以优化这些治疗酵素的稳定性、活性和标靶性。在监管激励措施、资金增加和蛋白质工程技术进步的共同推动下，孤儿药市场一直在稳步成长。这种增长鼓励了对罕见疾病研发的投资。罕见疾病领域学术研究人员、製药公司和患者权益团体之间的合作变得更加普遍。这种合作加速了基于蛋白质的疗法的研究和开发。致力于罕见疾病的患者团体和基金会的大力宣传努力提高了人们对研究和治疗发展的认识和支持。这些努力推动了对蛋白质工程解决方案的资助和兴趣。基因组学和蛋白​​质组学等诊断技术的进步使得罕见疾病特异性生物标记的鑑定成为可能。然后蛋白质工程可用于开发诊断和标靶治疗。这项因素将加速全球蛋白质工程市场的需求。

主要市场挑战

蛋白质设计的复杂性

蛋白质具有复杂的三维结构，这对其功能至关重要。设计具有正确折迭的特定结构的蛋白质是一项具有挑战性的任务，因为氨基酸序列的微小变化可能导致错误折迭和功能丧失。预测设计蛋白质的确切功能可能具有挑战性。许多蛋白质在生物系统中具有多方面的作用，设计蛋白质来执行特定功能可能非常复杂。确保设计的蛋白质稳定并正确折迭成其功能构像是一项重大挑战。实现正确的蛋白质折迭对其活性和功效至关重要。蛋白质经常与其他分子相互作用，例如配体、辅因子或其他蛋白质。设计与特定分子选择性且高亲和力相互作用的蛋白质可能很复杂。设计参与特定蛋白质-蛋白质相互作用的蛋白质尤其具有挑战性。预测不同蛋白质如何相互作用并准确地设计这些相互作用是很复杂的。蛋白质设计需要多个学科的专业知识，包括生物学、化学、生物资讯学和结构生物学。这些领域的专家之间的合作通常是必要的。

永续性和环境议题

蛋白质工程研究通常需要大量资源，包括实验室设备、消耗品和能源。这些资源密集型流程对环境的影响可能值得关注。蛋白质产品的生产，如治疗性蛋白质、酵素和替代蛋白质（如植物性和细胞性肉类），可能会对环境产生影响。优化生物製造流程以使其更具永续性是一项挑战。用于各种应用（包括农业和工业生物技术）的基因改造生物（GMO）的开发引起了环境和监管方面的担忧。确保基因改造生物的安全使用并解决潜在的生态影响至关重要。生物製造过程会产生废弃物和副产品，可能对环境造成影响。管理和最大限度地减少废物流是永续发展的挑战。许多蛋白质工程过程需要受控的环境和精确的条件，这可能是能源密集的。减少能源消耗和转向再生能源是永续发展的优先事项。在蛋白质工程中使用化学物质（例如用于 DNA 合成和蛋白质纯化的试剂）可能会对环境产生影响。开发更绿色的化学方法是永续发展目标。虽然替代蛋白（植物蛋白和细胞蛋白）通常被认为比传统畜牧业更具永续性，但它们的环境足迹可能会有所不同。减少这些技术对环境的影响是一项持续的挑战。

主要市场趋势

蛋白质工程的扩展

蛋白质工程用于修改作物的基因组成以增强特定性状。这可以包括增强对病虫害的抵抗力，提高对环境压力（例如干旱或盐度）的耐受性，以及优化营养成分。透过蛋白质工程开发具有增强抗病性的作物，减少了对化学农药的需求，有助于环境友善和永续农业。抗虫工程作物可以保护产量并减少对化学杀虫剂的依赖，对环境和农民都有好处。蛋白质工程可以帮助培育更能抵御干旱条件的作物，这对于面临缺水和气候变迁挑战的地区至关重要。蛋白质工程透过提高维生素和矿物质等必需营养素的含量来提高作物的营养价值。透过提高作物产量和减少对化学投入的需求，蛋白质工程作物可以为更永续和环境友善的农业实践做出贡献。使用透过蛋白质工程设计的基因改造作物可能会减少土壤侵蚀，降低温室气体排放，减少农业径流，从而减轻环境危害。生物强化涉及提高作物必需营养素的水平。蛋白质工程可以在主要作物的生物强化中发挥作用，以解决弱势群体的营养不良和营养缺乏问题。

细分市场洞察

技术洞察

2022 年，全球蛋白质工程市场理性蛋白质设计领域占据最大份额，预计未来几年将继续扩大。该技术在酵素工程和抗体开发方面的广泛应用占据了主导份额。酶工程的商业用途大幅增加，这导致了具有适当催化能力的改良和修饰酶的产生。定点诱变是理性设计工程方法中经常采用的方法，其高市场渗透率有助于推动该类别的发展。

产品类型见解

2022年，全球蛋白质工程市场单株抗体领域占据最大的收入份额，预计未来几年将继续扩大。用于创造治疗改进的单株抗体的研发支出不断增加，是影响这些技术利用率提高的主要因素之一。由于越来越多地使用标靶单株抗体来治疗癌症和其他慢性疾病，预计该细分市场很快就会成长。像这样，采用尖端技术的遗传平台的出现，例如用于实现有效蛋白质工程以开发单株抗体的下一代定序，预计将显着提高成长潜力。

最终用途见解

2022 年，全球蛋白质工程市场製药和生技公司细分市场占据最大份额，预计未来几年将继续扩大。其中很大一部分是由于电脑模拟药物研究模型在治疗神经系统问题、癌症和糖尿病方面的广泛使用的结果。这些企业不断努力透过使用电脑建模来创建专利到期药物的药物版本来保持其市场地位。该领域也受到公共和商业医疗保健组织不断增加的资金和财政支持的推动，这些资金和财政支持旨在创建复杂的蛋白质工程技术，从而改善患者的治疗效果。

区域洞察

2022年，北美地区在全球蛋白质工程市场中占据主导地位。该地区占据的较大比例可能是由于主要市场参与者为提高研发能力而推动的合作数量不断增加。高市占率受到该地区重要公司的影响，包括安捷伦科技公司和赛默飞世尔科技公司。

预计亚太地区在预测期内将以最快的CAGR成长。因为亚洲发展中国家自体免疫疾病、心血管疾病和癌症疾病的发生率很高。此外，印度和中国等新兴经济体的高速经济发展预计将支持该产业在该领域未开发前景的扩张。此外，预计该地区的扩张将得益于蛋白质工程应用研究和临床测试的大量人口基础。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球蛋白质工程市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型（胰岛素、单株抗体、凝血因子（血液因子 + 组织纤溶酶原）、疫苗、生长因子（荷尔蒙 + 细胞激素）和其他产品类型）
    • 按技术分类（非理性蛋白质设计和理性蛋白质设计）
    • 按最终用户（製药和生物技术公司、学术机构和合约研究组织 (CRO)）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：亚太地区蛋白质工程市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国蛋白质工程
    • 印度蛋白质工程
    • 澳洲蛋白质工程
    • 日本蛋白质工程
    • 韩国蛋白质工程

第 7 章：欧洲蛋白质工程市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美蛋白质工程市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美洲蛋白质工程市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲蛋白质工程市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非蛋白质工程
    • 沙乌地阿拉伯蛋白质工程
    • 阿联酋蛋白质工程

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 13 章：全球蛋白质工程市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第 15 章：大环境分析

第16章：竞争格局

  • 安捷伦科技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 安进公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 布鲁克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • Bio-Rad 实验室公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 礼来公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 默克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 诺和诺德公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 珀金埃尔默公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 赛默飞世尔科技公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 沃特世公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 金斯瑞美国公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 通用电气医疗集团
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建议

第 18 章：关于我们与免责声明

简介目录
Product Code: 16973

Global Protein Engineering Market has valued at USD 2.56 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 11% through 2028. Protein engineering is a branch of biotechnology that involves the deliberate design, modification, and optimization of proteins to create new functions, improve existing ones, or tailor them for specific applications. Proteins are essential biological macromolecules that perform a wide range of functions in living organisms, including catalyzing chemical reactions (enzymes), transporting molecules, providing structural support, and regulating cellular processes. Protein engineering harnesses the understanding of protein structure and function to manipulate these molecules for various purposes. Advances in molecular biology techniques have made it possible to synthesize and modify genes encoding proteins with specific sequences. This allows researchers to create entirely new proteins or modify existing ones for various applications.

The growing demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and other protein-based therapies, was a significant driver. Protein engineering techniques are essential for optimizing the production and efficacy of these drugs. Ongoing advancements in genomics, transcriptomics, and proteomics were providing valuable insights into the role of proteins in disease pathways. This knowledge fueled the demand for protein engineering techniques to develop targeted therapies. The biotechnology and pharmaceutical industries were experiencing sustained growth, with increased investment in research and development. This growth was driving the demand for protein engineering tools and services. Protein engineering was playing a crucial role in the development of therapies for rare and orphan diseases. The potential for high returns in this niche market was a driver for investment and innovation. Protein engineering was being used to design enzymes with enhanced properties for various industrial applications, including biofuel production, food processing, and waste management.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 2.56 Billion
Market Size 2028USD 4.76 Billion
CAGR 2023-202811.00%
Fastest Growing SegmentVaccines
Largest MarketNorth America

Technological Advancements

Technological advancements in protein engineering have played a pivotal role in shaping the field and expanding its applications in various industries, including pharmaceuticals, biotechnology, agriculture, and industrial processes. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) technology revolutionized protein engineering. It allows precise genome editing, making it possible to modify genes and engineer proteins with high specificity and efficiency. This has far-reaching implications in drug development, agriculture, and basic research. Directed evolution is a powerful technique that mimics natural selection to optimize proteins for specific functions. Through iterative rounds of mutation and selection, researchers can engineer proteins with enhanced properties, such as increased affinity, stability, or enzymatic activity. High-Throughput Screening (HTS) methods have become more sophisticated and automated, enabling the rapid screening of large libraries of proteins for desired properties. This accelerates the discovery of novel enzymes, therapeutic antibodies, and other protein-based products. Advances in computational methods, including molecular modeling and machine learning, allow researchers to predict the structure and function of engineered proteins. This saves time and resources in the design phase and helps in understanding protein-ligand interactions. Synthetic biology techniques enable the creation of entirely new proteins and biological systems. Researchers can design and synthesize genes encoding novel proteins with tailored functions, expanding the possibilities for protein engineering. Improvements in protein expression systems, such as yeast, bacteria, and mammalian cells, have enhanced the production of recombinant proteins and therapeutic antibodies. These advancements increase the yield and quality of engineered proteins.

Understanding protein folding and stability is crucial for protein engineering. Computational tools and experimental techniques have improved the prediction of protein structures and stability, aiding in the design of more robust proteins. Next-Generation Sequencing (NGS) technologies have facilitated the analysis of genetic variation and expression patterns, allowing researchers to identify and characterize potential protein engineering targets more effectively. Cell-free protein synthesis systems have become more efficient and versatile. They enable the rapid production of proteins without the need for living cells, making it easier to engineer and study various proteins. Recent developments in genome editing technologies like CrispRGold and Prime Editing offer even greater precision and control in modifying genetic sequences. These advancements have far-reaching implications for gene therapy and protein engineering. Techniques such as ChIP-seq and protein-DNA cross-linking enable researchers to study protein-DNA interactions at the molecular level. This is critical for understanding gene regulation and designing DNA-binding proteins. Advancements in single-cell proteomics technologies allow the profiling of individual cells' protein content, providing insights into cellular heterogeneity and disease mechanisms. This factor will help in the development of the Global Protein Engineering Market.

Growing Biotechnology and Pharmaceutical Sectors

The biotechnology and pharmaceutical industries have witnessed a shift towards biologics, which are drugs derived from living organisms. This includes monoclonal antibodies, vaccines, and other protein-based therapeutics. Protein engineering plays a crucial role in designing, optimizing, and producing these biologics, meeting the increasing demand for more targeted and effective treatments. The process of discovering and developing new drugs often involves the identification and modification of specific proteins associated with diseases. Protein engineering techniques enable the modification of these proteins to enhance their therapeutic properties or to create entirely new drug candidates. The pharmaceutical sector is increasingly moving towards personalized medicine, where treatments are tailored to individual patient profiles. Protein engineering allows for the customization of therapeutic proteins to match the genetic and molecular characteristics of individual patients, improving treatment outcomes. Protein engineering has been instrumental in the development of therapies for rare and orphan diseases, which may not have large patient populations. The pharmaceutical industry has shown interest in these niche markets, driving demand for protein engineering services and technologies.

The biopharmaceutical industry relies on biomanufacturing processes to produce large quantities of protein-based drugs. Protein engineering helps optimize the expression, yield, and stability of these therapeutic proteins, ensuring efficient and cost-effective production. Pharmaceutical companies continuously seek to expand their drug pipelines with innovative and differentiated products. Protein engineering allows for the development of novel biologics and protein-based therapies, helping companies stay competitive. The development of combination therapies, where multiple drugs are used to target different aspects of a disease, is a growing trend in the pharmaceutical sector. Protein engineering can be employed to design complementary therapeutic proteins that work together synergistically. As patents for some biologic drugs expire, there is a growing market for biosimilars, which are highly similar versions of existing biologics. Protein engineering is used to create biosimilars with comparable efficacy and safety profiles. Biotechnology and pharmaceutical companies invest heavily in research and development to bring new drugs to market. This investment includes funding for protein engineering research and technology development. Collaboration between pharmaceutical companies, biotech firms, and academic institutions in protein engineering research has become common. These partnerships drive innovation and accelerate the development of protein-based therapies. Events like the COVID-19 pandemic have highlighted the need for rapid vaccine and therapeutic development. Protein engineering played a pivotal role in the development of COVID-19 vaccines and treatments, showcasing its importance in addressing global health challenges. This factor will pace up the demand of the Global Protein Engineering Market.

Increased Focus on Rare Diseases

Rare diseases, also known as orphan diseases, often lack effective treatments due to their low prevalence. Protein engineering offers a promising approach to develop tailored therapies for these diseases, addressing significant unmet medical needs. The study of rare diseases often involves identifying specific genetic mutations or protein abnormalities that underlie these conditions. Protein engineering allows for the customization of therapeutic proteins to precisely target the molecular pathways involved in rare diseases, enabling precision medicine approaches. Governments and regulatory agencies worldwide provide incentives for the development of orphan drugs to treat rare diseases. Protein engineering is instrumental in designing and optimizing these drugs, including monoclonal antibodies and enzyme replacement therapies. Rare diseases are often caused by specific protein abnormalities. Protein engineering techniques enable the development of targeted therapies that can correct or compensate for these abnormalities, leading to improved treatment outcomes.

Monoclonal antibodies engineered to target rare disease-related proteins have shown significant promise in treating conditions such as certain forms of muscular dystrophy and lysosomal storage disorders. Protein engineering is closely linked to gene therapy, which holds great potential for treating rare genetic disorders. Engineered proteins, such as viral vectors or enzymes, can be used to deliver therapeutic genes to patients with rare diseases. For certain rare metabolic disorders, enzyme replacement therapies are essential. Protein engineering techniques can optimize the stability, activity, and targeting of these therapeutic enzymes. The orphan drug market has been growing steadily, driven by a combination of regulatory incentives, increased funding, and advances in protein engineering technologies. This growth encourages investment in research and development for rare diseases. Collaboration between academic researchers, pharmaceutical companies, and patient advocacy groups in the field of rare diseases has become more common. Such collaborations accelerate research and the development of protein-based therapies. Strong advocacy efforts by patient groups and foundations dedicated to rare diseases have raised awareness and support for research and treatment development. These efforts drive funding and interest in protein engineering solutions. Advances in diagnostic technologies, such as genomics and proteomics, enable the identification of rare disease-specific biomarkers. Protein engineering can then be used to develop diagnostics and targeted therapies. This factor will accelerate the demand of the Global Protein Engineering Market.

Key Market Challenges

Complexity of Protein Design

Proteins have complex three-dimensional structures that are crucial for their functions. Designing proteins with specific structures that fold correctly is a challenging task, as small changes in amino acid sequences can lead to misfolding and loss of function.Predicting the exact function of a designed protein can be challenging. Many proteins have multifaceted roles within biological systems, and designing a protein to perform a specific function can be highly complex. Ensuring that a designed protein is stable and properly folds into its functional conformation is a significant challenge. Achieving the correct protein fold is crucial for its activity and efficacy. Proteins often interact with other molecules, such as ligands, cofactors, or other proteins. Designing a protein that interacts selectively and with high affinity with a particular molecule can be complex. Designing proteins that engage in specific protein-protein interactions can be particularly challenging. Predicting how different proteins will interact with one another and engineering those interactions accurately is complex. Protein design requires expertise in multiple disciplines, including biology, chemistry, bioinformatics, and structural biology. Collaborations among experts in these fields are often necessary.

Sustainability and Environmental Concerns

Protein engineering research often requires substantial resources, including laboratory equipment, consumables, and energy. The environmental impact of these resource-intensive processes can be a concern. The production of protein-based products, such as therapeutic proteins, enzymes, and alternative proteins (like plant-based and cell-based meats), can have environmental implications. Optimizing biomanufacturing processes to be more sustainable is a challenge. The development of genetically modified organisms (GMOs) for various applications, including agriculture and industrial biotechnology, raises environmental and regulatory concerns. Ensuring the safe use of GMOs and addressing potential ecological impacts is essential. Biomanufacturing processes can generate waste and byproducts that may have environmental consequences. Managing and minimizing waste streams is a sustainability challenge. Many protein engineering processes require controlled environments and precise conditions, which can be energy intensive. Reducing energy consumption and transitioning to renewable energy sources are priorities for sustainability. The use of chemicals in protein engineering, such as reagents for DNA synthesis and protein purification, can have environmental impacts. Developing greener chemistry approaches is a sustainability goal. While alternative proteins (plant-based and cell-based) are often considered more sustainable than traditional animal agriculture, their environmental footprint can vary. Reducing the environmental impact of these technologies is an ongoing challenge.

Key Market Trends

Expansion of Protein Engineering

Protein engineering is used to modify the genetic makeup of crops to enhance specific traits. This can include increasing resistance to pests and diseases, improving tolerance to environmental stressors (e.g., drought or salinity), and optimizing nutritional content. Developing crops with enhanced disease resistance through protein engineering reduces the need for chemical pesticides, contributing to environmentally friendly and sustainable agriculture. Engineering crops for pest resistance can protect yields and reduce the reliance on chemical insecticides, benefiting both the environment and farmers. Protein engineering can help create crops that are more resilient to drought conditions, which is critical in regions facing water scarcity and climate change challenges. Protein engineering is applied to increase the nutritional value of crops by enhancing the content of essential nutrients, such as vitamins and minerals. By improving crop yields and reducing the need for chemical inputs, protein-engineered crops can contribute to more sustainable and environmentally friendly agricultural practices. The use of genetically modified crops designed through protein engineering may lead to reduced soil erosion, lower greenhouse gas emissions, and decreased agricultural runoff, thus mitigating environmental harm. Biofortification involves increasing the levels of essential nutrients in crops. Protein engineering can play a role in biofortifying staple crops to address malnutrition and nutrient deficiencies in vulnerable populations.

Segmental Insights

Technology Insights

In 2022, the Global Protein Engineering Market rational protein design segment held the largest share and is predicted to continue expanding over the coming years. The technology's vast application in enzyme engineering and antibody development accounts for the dominant share. Enzyme engineering has seen a tremendous increase in its commercial uses, which has led to the creation of improved and modified enzymes with the appropriate catalytic capabilities. Site-directed mutagenesis is one method that is often employed in rational design engineering approaches, and its high market penetration helps to drive the category.

Product Type Insights

In 2022, the Global Protein Engineering Market monoclonal antibodies segment held the largest revenue share and is predicted to continue expanding over the coming years. The rising R&D expenditure for creating therapeutically improved monoclonal antibodies is one of the main factors influencing the increased utilisation of these technologies. Soon, the segment is anticipated to grow due to the rising use of targeted monoclonal antibodies for the treatment of cancer and other chronic diseases. Like this, the emergence of genetic platforms that employ cutting-edge technology, such as next-generation sequencing for enabling effective protein engineering for the development of monoclonal antibodies, is anticipated to significantly boost the growth potential.

End Use Insights

In 2022, the Global Protein Engineering Market pharmaceutical & biotechnology companies segment held the largest share and is predicted to continue expanding over the coming years. The significant portion is a result of the expanding usage of in silico drug research models for the treatment of neurological issues, cancer, and diabetes. These businesses constantly strive to preserve their market presence by using computer modelling to create drug versions of patent-expiring medications. The segment is also being driven by the increasing funding and financial support from public and commercial healthcare organisations for the creation of sophisticated protein engineering technologies that will improve patient outcomes.

Regional Insights

The North America region dominated the Global Protein Engineering Market in 2022. The bigger proportion that this region has grabbed is probably due to the increasing number of collaborations that major market participants have promoted for improving their R&D capabilities. The high market share has been influenced by the existence of important companies in the area, including Agilent Technologies and Thermo Fisher Scientific, Inc.

The Asia Pacific region is projected to grow at the fastest CAGR over the forecast period. Because developing Asian nations have high rates of autoimmune, cardiovascular, and cancer diseases. Additionally, the high economic development in emerging economies like India and China is anticipated to support the sector's expansion in this area's unexplored prospects. Additionally, it is projected that the region's expansion will be aided by the availability of a sizable population base for the research and clinical testing of protein engineering applications.

Key Market Players

  • Agilent Technologies Inc.
  • Amgen Inc.
  • Bruker Corporation
  • Bio-Rad Laboratories Inc.
  • Eli Lilly and Company
  • Merck KGaA
  • Novo Nordisk AS
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • Genscripts USA, Inc.
  • GE Healthcare

Report Scope:

In this report, the Global Protein Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Engineering Market, By Product Type:

  • Insulin
  • Monoclonal Antibodies
  • Coagulation Factors (Blood Factors + Tissue Plasminogen)
  • Vaccines
  • Growth Factors (Hormones + Cytokine)
  • Other Product Types

Protein Engineering Market, By Technology:

  • Irrational Protein Design
  • Rational Protein Design

Protein Engineering Market, By End User:

  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions
  • Contract Research Organizations (CROs)

Global Protein Engineering Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Protein Engineering Market.

Available Customizations:

  • Global Protein Engineering Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Engineering Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), and Other Product Types)
    • 5.2.2. By Technology (Irrational Protein Design and Rational Protein Design)
    • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations (CROs))
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Protein Engineering Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Protein Engineering Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End User
    • 6.3.2. India Protein Engineering Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Protein Engineering Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Protein Engineering Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Technology
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Protein Engineering Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Technology
        • 6.3.5.2.3. By End User

7. Europe Protein Engineering Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Protein Engineering Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Protein Engineering Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Protein Engineering Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Type
    • 7.3.4. Italy Protein Engineering Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Protein Engineering Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End User

8. North America Protein Engineering Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Protein Engineering Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Protein Engineering Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Protein Engineering Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End User

9. South America Protein Engineering Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Protein Engineering Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Protein Engineering Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Protein Engineering Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End User

10. Middle East and Africa Protein Engineering Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Protein Engineering Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Protein Engineering Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Protein Engineering Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Protein Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Agilent Technologies Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Amgen Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Bruker Corporation
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Bio-Rad Laboratories Inc.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Eli Lilly and Company
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Merck KGaA
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Novo Nordisk AS
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. PerkinElmer Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Thermo Fisher Scientific Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Waters Corporation
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
  • 16.11. Genscripts USA, Inc.
    • 16.11.1. Business Overview
    • 16.11.2. Company Snapshot
    • 16.11.3. Products & Services
    • 16.11.4. Financials (In case of listed companies)
    • 16.11.5. Recent Developments
    • 16.11.6. SWOT Analysis
  • 16.12. GE Healthcare
    • 16.12.1. Business Overview
    • 16.12.2. Company Snapshot
    • 16.12.3. Products & Services
    • 16.12.4. Financials (In case of listed companies)
    • 16.12.5. Recent Developments
    • 16.12.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer